Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3166350 | 0.82 | POLB (0.51) | MAPTHTTSMN1; SMN2NPC1LMNA | |
| SCHEMBL3175750 | 0.80 | EPHX2 (0.56) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL5963579 | 0.80 | EPHX2 (0.56) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL5964054 | 0.79 | EPHX2 (0.54) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL10937020 | 0.73 | MAPT (0.59) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL5862047 | 0.72 | HTT (0.55) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL5049577 | 0.71 | EPHX2 (1.00) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL3454750 | 0.71 | EPHX2 (1.00) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 | |
| SCHEMBL23567195 | 0.70 | MAPT (0.47) | EPHX2MAPTHTTSMN1; SMN2NPC1 | |
| SCHEMBL10684986 | 0.70 | HTT (0.76) | EPHX2MAPTHTTCYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016399-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2010-01-21 | — | — | US | disclosed |
| US-20100016399-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | AHMAD NADIA MAMOONA | 2010-01-21 | — | — | US | disclosed |
| WO-2008092873-A1 | GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | GLAXO GROUP LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016399-A1 | GLYT1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders | SLC18A2, SLC1A2, SLC1A1 | EPHX2 3235/4885MAPT 107/4885HTT 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.